Amazon expands list of HIPAA eligible AI services

Amazon Web Services (AWS) is adding to its list of HIPAA eligible machine-learning services.

Amazon Translate, Amazon Comprehend and Amazon Transcribed are now U.S. HIPAA eligible services, the company announced last week in a blog post. Prior to the announcement, AWS already had three AI services that were HIPAA eligible: Amazon Polly, Amazon SageMaker and Amazon Rekognition.

“By using these services, AWS customers in the healthcare industry can leverage data insights to deliver better outcomes for providers and patients using the power of machine learning (ML),” the blog post stated. “To support our healthcare customers, AWS HIPAA eligible services enable covered entities and their business associates subject to HIPAA to use the secure AWS environment to process, maintain, and store protected health information."

NextGen Healthcare, Omada Health, Verge Health and Orion Health are already running HIPAA workloads on AWS to analyze patient records, according to Amazon.

The three services have various capabilities:

  • Amazon Transcribe is a speech-to-text service that automatically creates text transcripts from audio files. 
  • Amazon Translate is a neural machine-learning language translation service. 
  • Amazon Comprehend is a natural language processing service used to analyze unstructured text.

Amazon has made a string of moves in the healthcare industry as of late, including recently filing a patent for a newer version of its virtual assistant Alexa that can detect when a user is sick. Additionally, it has teamed up with the Arcadia Group to sell a brand of medical products exclusively.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.